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ABSTRACT
Objective: To capture the clinical patterns, timing of
key milestones and survival of patients presenting with
amyotrophic lateral sclerosis/motor neuron disease
(ALS/MND) within Australia.
Methods: Data were prospectively collected and were
timed to normal clinical assessments. An initial
registration clinical report form (CRF) and subsequent
ongoing assessment CRFs were submitted with a
completion CRF at the time of death.
Design: Prospective observational cohort study.
Participants: 1834 patients with a diagnosis of ALS/
MND were registered and followed in ALS/MND clinics
between 2005 and 2015.
Results: 5 major clinical phenotypes were determined
and included ALS bulbar onset, ALS cervical onset and
ALS lumbar onset, flail arm and leg and primary lateral
sclerosis (PLS). Of the 1834 registered patients, 1677
(90%) could be allocated a clinical phenotype. ALS
bulbar onset had a significantly lower length of survival
when compared with all other clinical phenotypes
(p<0.004). There were delays in the median time to
diagnosis of up to 12 months for the ALS phenotypes,
18 months for the flail limb phenotypes and 19 months
for PLS. Riluzole treatment was started in 78–85% of
cases. The median delays in initiating riluzole therapy,
from symptom onset, varied from 10 to 12 months in
the ALS phenotypes and 15–18 months in the flail limb
phenotypes. Percutaneous endoscopic gastrostomy
was implemented in 8–36% of ALS phenotypes and
2–9% of the flail phenotypes. Non-invasive ventilation
was started in 16–22% of ALS phenotypes and
21–29% of flail phenotypes.
Conclusions: The establishment of a cohort registry
for ALS/MND is able to determine clinical phenotypes,
survival and monitor time to key milestones in disease
progression. It is intended to expand the cohort to a
more population-based registry using opt-out
methodology and facilitate data linkage to other
national registries.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) has a
heterogeneous clinical presentation, with
consequent variability in disease progression
and survival.1 The clinical categories and
nosology of ALS have evolved over many
years of observational studies resulting in a
deﬁned set of diagnostic criteria.2–5 The
health service needs of ALS patients and
their carers require integrated services across
the allied health disciplines along with neur-
ology, respiratory and palliative medicine spe-
cialists.6–8 A critical issue remains the timely
diagnosis, clinical classiﬁcation and prognos-
tic stratiﬁcation (staging) of patients that
facilitate appropriate care plans. The primary
objective of the Australian Motor Neurone
Disease (MND) registry was to develop accur-
ate clinical phenotyping and survival data,
enabling early pathways to interventions and
clinical trial enrolment.9–12
There have been advances in prognostic
modelling for survival and staging of
Strengths and limitations of this study
▪ Outcomes and time to key interventions were
easily obtained and recorded using the national
web-based data entry reducing issues of recall
error.
▪ Based on the site of disease onset and distribu-
tion of regional involvement, with respect to
upper and lower motor neuron signs, patients
could be assigned to clinical phenotypes.
▪ Selection bias due to capture and follow-up of
patients from specialised clinics could alter out-
comes and survival compared with those not
attending specialised clinics.
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ALS/MND.11 13 In addition, the use of patient registries
and cohort studies to monitor disease-speciﬁc patient
care and outcomes has developed worldwide over the
past decade. Evidence from the Irish Registry indicated
that attendance at ALS multidisciplinary clinics itself
conferred a survival advantage.14 Disease registries
provide effective mechanism to further optimise and
inform clinical care and actively recruit into clinical
trials, bio-banking and research programmes for ALS/
MND. International data linkage will be essential in
furthering our understanding and delivering the
promise of treatments and a cure for ALS (NETCALS,
EURO-MOTOR, CARE). The Australian National MND
registry represents the Australian experience and pro-
vides a potentially practical mechanism for clinical phe-
notyping, monitoring and benchmarking clinical
practice at a national level.
The Australian MND registry is an observational
cohort study initiated in 2004.15 16 This registry has col-
lected a data set of, demographic, clinical proﬁles and
disease progression data at a national level from 2005 to
2015.15 In Australia, this methodology was initially devel-
oped within a single comprehensive ALS clinic,17 and
then expanded to a national level. The primary aim of
the national registry was to help coordinate focused care
and a foundation for case ascertainment for research in
ALS/MND.
METHODS
Consecutive patients in whom the treating neurologist
felt had a likely diagnosis of ALS/MND were invited to
participate in the national registry. ALS/MND care deliv-
ery in Australia is through 10 major clinics and the state-
based motor neuron disease associations. These ALS/
MND clinics provide comprehensive care with allied
health teams. In most clinics, there is a link to the MND
associations of each state. Ethics approval was obtained
from appropriate institutional review committees across
each state and prior to enrolment in the registry.
Patients gave written informed consent for their partici-
pation. Non-English-speaking patients were required to
have an English-speaking care provider/relative or an
interpreter to provide informed consent before data col-
lection. Patients incapable of providing written consent
needed a witness to sign and acknowledge verbal
consent. In 2013, opt-out consent was instituted as the
method of registration in the State of Victoria. Patients
registered who were later deemed not to have ALS were
removed from the analysis after submission of a comple-
tion clinical report form (CRF).
Once registered, patient baseline details were entered
using a registration CRF. Further CRFs were submitted at
varying intervals as part of patient’s ongoing clinical
assessments. Information collected at registration and
follow-up reviews related to the clinical history of disease
and its progression, current clinical signs, medications,
respiratory function, body weight, clinical interventions
and health service utilisation. The ﬁndings on neuro-
logical examination were designed to identify speciﬁc
clinical phenotypes. Further information in the domains
of evolution of clinical signs, ALSFRS-r, diagnostic tests,
body weight and respiratory function are gathered at
subsequent clinical reviews. Timing of interventions,
including percutaneous endoscopic gastrostomy (PEG),
medications and non-invasive ventilation (NIV), along
with health service utilisation are prospectively collected.
The data set was analysed using R (http://www.r-project.
org/). Patients included in the analysis all had a com-
pleted registration CRF, with date of birth, time and
region of symptom onset, there were no missing data.
Patients were enrolled in the cohort registry using a
web-based system which produced a unique patient iden-
tiﬁcation number for each patient entered. The link
between the patient’s identity and the patient ID
number was kept secure at each study site. Once regis-
tered, the patient ID number, study centre number and
investigator number were required for all data entry.
CLINICAL PHENOTYPES
A primary aim of this cohort study was to determine
whether ALS/MND patients could be classiﬁed into clin-
ical phenotypes at a national level across multiple ALS/
MND clinics. The rationale for this was to facilitate clin-
ical care and research based on an appropriate patient
stratiﬁcation and then benchmark between centres in
relation to major interventions and survival.18
The methodology for determining the three major
clinical phenotypes was adapted from an initial study
undertaken in a large multidisciplinary ALS MND clinic
and a previous studies analysis of ﬂail phenotypes.17 19
The region of symptom onset is combined with the
observed clinical UMN/LMN signs in the bulbar, cer-
vical and lumbar regions (ﬁgure 1). Those patients
without such clinical information in the CRF were
deﬁned as undifferentiated. Phenotyped patients were
also given an El Escorial classiﬁcation based on the clin-
ical information in the most recent CRF.2 3 The three
major clinical phenotypes, as adapted from El Escorial,
are illustrated in ﬁgure 1.
Survival and clinical phenotypes interventions and
outcomes
Patient survival was determined from the date of
symptom onset to the date of death. Death was reported
via submission of a completion CRF. For the
Kaplan-Meier curves, patients were censored at the time
of death according to the allocated clinical phenotype
(ﬁgure 2).
RESULTS
Registrations
A total of 1834 patients were registered in the cohort
study between 2005 and 2015. In 1677 (90%) patients, a
registration CRF was available and these were included
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in the analysis. Ten major centres from around Australia
accounted for 95% of all patient registrations. This study
cohort overall had a gender ratio male to female of
1.5:1.0, with registration in AMNDR occurring at a
median of 17 months from symptom onset. The
number, gender, age at onset, time to registration and
number of deaths for each site in the study cohort are
detailed in table 1.
Figure 2 Kaplan-Meier curves
of patients censored at the time of
death according to clinical
phenotype. Survival according to
the phenotypes with amyotrophic
lateral sclerosis bulbar, onset
having significantly different
curves to flail arm and leg
(p<0.003 and <0.004).
Figure 1 The clinical phenotypes are detailed, amyotrophic lateral sclerosis, flail and primary lateral sclerosis (PLS). Clinical
phenotypes are allocated by identifying the region of symptom onset combined with the segmental distribution of upper and lower
motor neuron signs. Patients with combined upper and lower motor neuron signs in one segment with at least one other segment
involved with either upper motor neuron (UMN) and/or lower motor neuron (LMN) signs are classified into a clinical phenotype.
Flail arm have the initial onset of LMN signs in the arms and absent arm reflexes. They have UMN and/or LMN signs in the legs
and variable bulbar involvement and evolving neck weakness. Flail leg begin with LMN signs in the legs and areflexia, which
extend to the arms with very late bulbar involvement. PLS is defined by having only UMN signs in all three segments; the onset
can be in any region. Definitions for UMN and LMN signs for each region are listed. In order to maintain consistency, a region
required the presence of at least one of the predefined clinical signs listed in the panel in order to be designated as having UMN,
LMN or combined UMN/LMN signs.
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According to gender, the median age of symptom
onset was similar for all centres (male 60 years; female
62 years). Each centre contributed a similar percentage
of completion CRFs which provided the date of death
and survival data. Assuming an incidence of 2/100 000
in Australia,20 there would have been ∼5000 incident
cases of ALS during 2004–2014. As such, the present
study cohort would represent ∼35% of incident ALS
cases in Australia during the study period.
Clinical phenotyping
The ALS phenotype (bulbar, cervical and lumbar onset)
was the most frequent phenotype, accounting for 1275
(76%) of the cohort cases (table 1). Within the ALS
phenotypes, the subgroups were evenly distributed:
bulbar onset 26%, cervical onset 24% and lumbar onset
27% (table 1). Flail limb subgroups represented 9%,
undifferentiated group 9% and primary lateral sclerosis
(PLS) 5% of all cases (table 1). Importantly, the major
sites registered similar percentages of patients across
each of the clinical phenotypes, providing some conﬁ-
dence that the methodology was broadly applicable. The
undifferentiated entity provided a clinical ‘holding
pattern’ for those cases where there was diagnostic
uncertainty and an inability to allocate a clinical pheno-
type based on the entered data. As subsequent assess-
ments were entered if patients fulﬁlled the classiﬁcation
criteria, their clinical phenotype was updated.
The gender ratios for the different clinical phenotypes
indicated a clear male predominance for all phenotypes
with the exception of ALS bulbar onset (table 1). As pre-
viously shown, this subgroup has a high proportion of
females compared with other subgroups.17 The ﬂail arm
and leg phenotypes have a much higher proportion of
males to females as has been established in other
studies.19
Sixty-three per cent of the cohort were deﬁned as def-
inite or probable ALS using the El Escorial classiﬁcation
(table 1). The ALS phenotypes contributed 62% of all
deﬁnite or probable El Escorial cases, ALS bulbar onset
contributing 20%, ALS cervical onset 18% and ALS
lumbar onset 23% (table 1). The ﬂail groups contribute
much less to the deﬁnite and probable El Escorial
groups, 1% in total. The undifferentiated were not classi-
ﬁed into a phenotypic group or given an El Escorial
classiﬁcation.
Survival
Of all 763 patients with a date of death from the present
cohort, the ALS bulbar onset exhibited the shortest
median survival of 24 months from symptom onset,
while PLS had the longest, 73 months (ﬁgure 3). The
survival of ALS bulbar onset was signiﬁcantly different
from all other phenotypes consistent with other reports
on ALS survival.14 21 22 The Kaplan-Meier (KM) curves
for clinical phenotypes are also similar to other reports
(ﬁgure 2). The undifferentiated group had similar
survival curves to ALS cervical/lumbar onset. It is
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conjecture whether the clinical phenotypes relate to var-
iations in pathophysiology, but they do represent
patients with similar survival times and clinical care
requirements.
Timelines to key milestones and clinical interventions
according to clinical phenotype
The median time to diagnosis from symptom onset in
the ALS phenotypes was 10–12 months. The ﬂail group
required 14–18 months and PLS the longest, at a
median of 19 months (table 2).
Diagnostic delay reﬂects a multitude of variables
which are related to health systems, referral patterns and
the difﬁculty of establishing a diagnosis in ALS. These
data provide a basis for analysis of any future interven-
tion designed to impact on diagnostic delay (such as a
diagnostic biomarker or health system change) at a
national and individual clinic level.
The initiation of riluzole treatment closely followed diag-
nosis and had a consistent uptake across all ALS phenotypes
being between 78% and 85% of cases with a median delay
of 10–12 months from symptom onset (table 2). The time
from symptom onset to NIV and PEG tube insertion are
reﬂective of the natural progression of ALS (table 2). The
percentage of cases getting PEG interventions is uniform
across the clinical phenotypes with the exception of ALS
bulbar onset which has the highest rate of insertion, 36% of
cases with a median time to insertion of 17 months from
symptom onset. Flail leg had only one case of PEG insertion
which is consistent with the lack of bulbar involvement in
this form of MND. The rates for PEG insertion and time to
insertion are consistent with other reported studies, with
bulbar onset disease is more likely to undergo PEG inser-
tion.23–25 NIV appeared to be uniformly applied across the
different phenotypes, with the ﬂail limb phenotype having
the longest interval from symptom onset to initiation of
NIV (33–37 months). Overall, the rates of implementation
NIV are similar to reported studies in North America and
Europe.26 27 There were no patients reported in the registry
who underwent tracheostomy. In the PLS group, it is inter-
esting to note that riluzole treatment and PEG insertion
preceded the conﬁrmation of diagnosis (table 2).
DISCUSSION
The primary objective of the present study was to deter-
mine whether clinical phenotypes could be identiﬁed in
Figure 3 All cases with a
reported date of death, median
(StdDev) survival in lunar months
according to clinical phenotype.
Table 2 Delay in diagnosis from symptom onset according to clinical phenotype (median; months) and time to key
interventions from symptom onset (riluzole treatment, non-invasive ventilation and percutaneous gastrostomy), with the
percentage of patients in the clinical phenotype who received the intervention
Phenotype
Total in
phenotype
Diagnosis from
symptom onset
median time,
months
Riluzole treatment
median time,
months (n, % of
phenotype)
Non-invasive
ventilation median
time, months (n, % of
phenotype)
Percutaneous
endoscopic gastrostomy
median time, months
(n, % of phenotype)
ALS bulbar
onset
429 10 10 (333, 78) 17 (68, 16) 17 (156, 36)
ALS cervical
onset
396 11 11 (337, 85) 18 (88, 22) 21 (48, 12)
ALS lumbar
onset
450 12 12 (358, 80) 23 (78, 17) 24 (35, 8)
Flail_arm 101 14 15 (83, 82) 33 (29, 29) 43 (9, 9)
Flail_leg 47 18 18 (38, 81) 37 (10, 21) 34 (1, 2)
PLS 84 23 16 (46, 55) 23 (9, 11) 15 (12, 14)
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a national registry across multiple ALS/MND clinics. The
present data provide a platform from which clinical phe-
notyping/staging of ALS patients with similar survival tra-
jectories can be compared between treatment centres.
This cohort is in line with previous studies evaluating clin-
ical phenotypes and survival characteristics.19 26 28 29
Preliminary analysis demonstrated that the ALS pheno-
type was the predominate group in the clinically deﬁnite
and probable El Escorial categories. The present categor-
isation of patients utilised a simple algorithm that is
readily applied during routine clinic consultations. This
approach has proven sustainable at a national level over
the past 10 years and, as such, provides a foundation for
delivery of care, benchmarking, quality and safety moni-
toring and potentially more detailed research on the
effect of therapies and interventions.
The time to diagnosis remains lamentably long and
any advances that shorten this period will deliver bene-
ﬁts to ALS patients and their carers. This is as much to
do with provision of resources and referral patterns, as it
is to do with the difﬁculty of making a diagnosis in ALS/
MND. It would be interesting to determine what future
interventions will reduce the delay in diagnosis at the
individual centre and national level.
Some major issues regarding cohort data are the
biases incurred from the opt-in consent methodology
and patient enrolments from specialist centres which
can skew the outcomes.30 31 The introduction of opt-out
consent may enhance case ascertainment, making
outcome analysis more representative of a population-
based approach to data acquisition. As the functionality
of patient registries evolve, especially in rare diseases,
new methods of patient participation, data acquisition
and methods of analysis will need to be explored.32 33
The reﬁnement of staging disease progress will further
enhance clinical management of ALS. Clinical pheno-
typing and staging should be designed to provide com-
plementary information. This approach may assist in the
discovery of biomarkers by providing analysis of patients
with similar clinical patterns and stage of disease. The
effort of developing and reﬁning these investigative
methodologies will prove to be valuable assets in trial
design, recruitment and implementation.34 35 Clinical
phenotyping and staging will inevitably permit better
randomisation in clinical trials and facilitate more rele-
vant outcome measures and an accurate assessment of
disease progression. The Australian MND registry will
now undergo revision and expansion of data-ﬁelds,
incorporating metrics of disease progression and
quality-of-life measures. Consent for de-identiﬁed data
collection will be changed from opt-in to opt-out across
Australia. Registries have the potential to be a single
point for enrolling and phenotyping patients for prote-
omic/genomic analysis and therapeutic trials.
Conclusions
The Australian MND registry has proven to be a success-
ful and sustainable method of registering, phenotyping
and observing key interventions in ALS/MND treat-
ment. It provides the ability to benchmark between
centres and provides national averages for key interven-
tions and disease progression. Further international
data-linkage, opt-out methodology for registration and
the addition of patient initiated information may further
enhance data quality and clinical trial enrolment.
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